Adjuvant chemotherapy decisions in clinical practice for early-stage node-negative, estrogen receptor-positive, HER2-negative breast cancer: Challenges and considerations

Keyphrases

• Clinical Practice 100%
• Adjuvant Chemotherapy 100%
• Estrogen Receptor-positive 100%
• HER2-negative Breast Cancer 100%
• Node-negative 100%
• Breast Cancer 50%
• Postmenopausal Women 50%
• Estrogen Receptor 50%
• Prognosticate 50%
• Clinical Scenarios 50%
• Patient Demographics 50%
• Oncologists 50%
• Clinical Parameters 50%
• Oncology 50%
• Recurrence Risk 50%
• Risk of Death 50%
• Complex Tumor 50%
• Pathologic Parameters 50%
• Clinical Decision-making 50%
• NCCN Clinical Practice Guidelines 50%
• Molecular Heterogeneity 50%
• Multigene 50%
• Stage I Breast Cancer 50%
• Negative Lymph Nodes 50%
• HER2-positive 50%
• Complex Genomes 50%
• Tumor Genome 50%
• Oncotype DX 50%
• Traditional Biomarkers 50%
• Lymph Node-negative Breast Cancer 50%

Medicine and Dentistry

• Estrogen Receptor 100%
• Breast Cancer 100%
• Adjuvant Chemotherapy 100%
• Biological Marker 50%
• Recurrent Disease 50%
• Neoplasm 25%
• Lymph Node 25%
• Postmenopause 25%
• Oncology 25%
• Patient Population 25%
• Oncologist 25%
• Clinical Decision Making 25%
• Oncotype DX 25%